Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 1123-1132

  Elhalawani, Hesham ^a   Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Gastric cancer; Gastroesophageal cancer; Ramucirumab

Indexed keywords

BEVACIZUMAB; RAMUCIRUMAB; VASCULOTROPIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; DIGESTIVE SYSTEM PERFORATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; GASTROESOPHAGEAL CANCER; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOGENICITY; LEUKOPENIA; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PROTEINURIA; REVIEW; STOMACH CANCER; STOMATITIS; TREATMENT INDICATION;

EID: 84938236267     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S71045     Document Type: Review

References (72)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [webpage on the internet]. Lyon: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr/Default.aspx. Accessed March 19, 2015.
2. Forman D, Burley V. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–649.
3. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol/Hematol. 2015;93(1):18–27.
4. Mihaljevic AL, Friess H, Schuhmacher C, et al. Clinical trials in gastric cancer and the future. J Surg Oncol. 2013;107(3):289–297. doi:10.1002/Jso.23120.
5. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–3079. doi:10.1245/s10434-010-1362-z.
6. Kitagawa Y, Takeuchi H, Takagi Y, et al. Sentinel node map­ping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol. 2013;31(29):3704–3710. doi:10.1200/JCO.2013.50.3789.
7. National Comprehensive Cancer Network. NCCN guidelines for gastric cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 19, 2015.
8. Hopkins S, Yang GY. FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol. 2011;2(1):39–44. doi:10.3978/j.issn.2078-6891.2010.004.
9. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
10. Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemo­radiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366:2074–2084.
11. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–4997.
12. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxalipla­tin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
13. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–4393.
14. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.
15. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013;39(1):60–67. doi:10.1016/j.ctrv.2012.09.007.
16. Oba K, Paoletti X, Bang YJ, et al; GASTRIC Group. Role of chemo­therapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer. 2013;49(7):1565–1577. doi:10.1016/j.ejca.012.12.016.
17. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064.
18. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combi­nation with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
19. ESMO guidelines working group. European Society of Medical Oncol­ogy (ESMO) guidelines for Gastric Cancer. Available from: http://www.esmo.org/Guidelines-Practice/Clinical-Practice- Guidelines/Gastrointestinal-Cancers/Gastric-Cancer. 2015 Accessed March 2015.
20. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–4444.
21. Kim HS, Kim HJ, Kim SY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24:2850–2854.
22. Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol. 2010;36:1172–1179.
23. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel arm, phase II trial. J Clin Oncol. 2013;31:3219–3225.
24. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39.
25. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside. Crit Rev Oncol/Hematol. 2014;94(1): 45–54.
26. Ellis L, Hicklin D. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–591.
27. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.
28. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603.
29. Burgos H. Angiogenic and growth factors in human amnio-chorion and placenta. Eur J Clin Invest. 1983;13:289–296.
30. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977;14:53–65.
31. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–858.
32. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its recep­tors. Nat Med. 2003;9(6):669–676.
33. Abdel-Rahman O. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol. 2014;35(11):10615–10625.
34. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest. 2007;37(11):878–886.
35. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF recep­tor signalling – in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–371.
36. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358: 2039–2049.
37. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12(17):5018–5022.
38. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–591.
39. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
40. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immu­noglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–787.
41. Lu D, Shen J, Vil MD, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003;278:43496–43507.
42. Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF bio­logical activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun. 2006;345:438–445.
43. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer. 2002;38:1133–1140.
44. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothe­lial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 2003;17:604–611.
45. Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth fac­tor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–1237.
46. Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase Ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015;20(5):493–494.
47. Eli Lilly and Company. Ramucirumab: Prescribing Information; 2014. Available form: http://www.accessdatafdagov/drugsatfda_docs/label/2014/125477lblpdf. March 19, 2015.
48. Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab (RAM) plus FOL­FOX as front-line therapy (Rx) for advanced gastric or esophageal ade­nocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014;32:5s. (Suppl; abstr 4004).
49. Wilke H, Muro K, Van Cutsem EV, et al. Ramucirumab plus pacli­taxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235.
50. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or rego­rafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol/Hematol. 2014;92(3):194–207.
51. Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol/Hematol. 2014;89(3):394–403.
52. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol. 2014;10(12):1981–1992.
53. Santoni M, Conti A, Massari F, et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer. 2015;136(1):1–10.
54. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta-analysis. Expert Rev Anticancer Ther. 2015;15(1):129–141.
55. Full Prescribing Information: Stivarga. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf. Accessed April 10, 2013.
56. Full Prescribing Information: Avastin. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s267lbl.pdf. Accessed April 10, 2013.
57. Full Prescribing Information: Zaltrap. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf. Accessed April 10, 2013.
58. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–3976.
59. Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168–176.
60. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201–5206.
61. Uronis HE, Bendell JC, Altomare I, et al. A phase II study of capecit­abine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist. 2013;18(3):271–272.
62. Pasquier E, Honore S, Pourroy B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005;65(6):2433–2440.
63. De Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–1233.
64. Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;47: 1511–1520.
65. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29:1449–1458.
66. Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesopha­geal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28:2947–2951.
67. Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in com­bination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2012;69:439–446.
68. Potts SJ, Huff SE, Lange H, et al. Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer. Appl Immunohistochem Mol Morphol. 2013;21(1):21–30. doi:10.1097/PAI.0b013e31825552a3.
69. Durães C, Almeida GM, Seruca R, et al. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464(3):367–378. doi:10.1007/s00428-013-1533-y.
70. Abdel-Rahman O. Targeting the hepatocyte growth factor/mesen­chymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev Anticancer Ther. 2015; 15(2):235–245.
71. Abdel-Rahman O. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. Med Oncol. 2015;32(1):431.
72. Abdel-Rahman O. Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic poten­tials. Tumor Biol. 2015;36(3):1367–1374.